Features and benefi ts of using new forms of antibiotics with improved pharmacokinetic properties

   Antibiotics remain one of the most popular classes of drugs used in modern medicine. The high medical and social significance of infections, their tendency to epidemic spread, places high demands on the effectiveness and safety of antibiotic therapy. Limitations in the development of new antibiotics, the emergence of new infectious outbreaks, and the growing problem of antibiotic resistance make the optimization of dosing regimens and the use of antibacterial drugs relevant. The article considers the possibilities and effectiveness of the use of modern forms of antibiotics with improved pharmacokinetic properties. The opinion that existed in the medical environment for a long time about the greater effectiveness of parenteral forms of antimicrobial drugs has recently been refuted. The innovative technology for creating dispersible tablets proposed at the beginning of the 21st century proved the comparability of both therapeutic concentrations of an antibiotic when using dispersible forms of an antibiotic and parenteral forms of administration, and the clinical effectiveness of their use. The manufacturing technology of dispersible forms consists in the fact that the tablet is formed from a plurality of microspheres consisting of a filler and an active substance, which creates conditions for protecting the microspheres from the influence of the acidic environment of the stomach and ensures the release of the active substance when exposed to bicarbonates in the intestine, i.e. in the zone of maximum antibiotic absorption. All this contributes to a higher bioavailability of the drug compared to tablet forms, and also provides more uniform dosing and, as a result, predictability of pharmacokinetics. This dosage form differs from traditional oral dosage forms in higher bioavailability of active substances, comparable to injectables, as well as a number of advantages that improve compliance. The improved pharmacokinetic profile of these forms of antibiotics is intended to provide higher clinical efficacy and tolerability and help reduce antibiotic resistance.

1. Lim S. S., Vos T., Flaxman A. D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 // Lancet. 2013; 80: 2224-2260. DOI: 10.1016/S0140-6736(12)61766-8.

2. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 // Lancet. 2013; 380: 2095-2128.

3. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. 2020; 395 (10229): 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3.

4. Fleming-Dutra K. E., Hersh A. L., Shapiro D. J., et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011 // JAMA. 2016; 315: 1864-1873. DOI: 10.1001/ jama.2016.4151.

5. Harbarth S., Balkhy H. H., Goossens H., et al. Antimicrobial resistance: one world, one fight! // Antimicrob Resist Infect Control. 2015; 4: 49.

6. Hoyert D. L., Xu J. Death: preliminary data for 2011 // Natl Vital Stat Rep. 2012; 61: 1-51

7. Ewig S., Birkner N., Strauss R., et al. New perspectives on communityacquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality // Thorax. 2009; 64: 1062-1069.

8. Вёрткин А. Л. Оптимизация эмпирической терапии внебольничной пневмонии у больных пожилого и старческого возраста / А, Л. Вёрткин [и др.] // РМЖ. – 2002. – 16: 708-712. [Vertkin A. L., Prokhorovich E. A., Namazova L. S. et al. Optimization of empiric therapy for community-acquired pneumonia in elderly and senile patients // Russkiy meditsinskiy zhurnal (Russian Medical Journal). 2002; 16: 708-712. (In Russ.)]

9. Зырянов С. К. Использование новых лекарственных форм антибиотиков как путь повышения эффективности и безопасности антибактериальной терапии / С. К. Зырянов, Е. А. Байбулатова // Антибиотики и химиотерапия. – 2019. – 64. – 81-91. [Zyryanov S. K., Baybulatova E. A. The use of new dosage forms of antibiotics as a way to improve the effectiveness and safety of antibiotic therapy // Antibiotics and chemotherapy. 2019, 64; 81-91. (In Russ.)]

10. Кнорринг Г. Ю. Интенсификация антибактериальной терапии при гнойно-воспалительных заболеваниях / Г. Ю. Кнорринг [и др.] // Военно-медицинский журнал. – 2008. – 329 (10). – 35-41. [Knorring G. Yu., Sternin Yu. I., Minaev S. V., Novozhilov A. A. Intensification of antibiotic therapy for pyoinflammatory diseases // Voenno-meditsinskii zhurnal. 2008; 329 (10): 35-41. (In Russ.)]

11. Сидоренко С. В. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике/ Евразийские клинические рекомендации / С. В. Сидоренко [и др.] // Педиатрия (Прил. к журн. Consilium Medicum). – 2017. – 1. – 17-25. [Sidorenko S. V., Yakovlev S. V., Spichak T. V. et al. Strategy and tactics of the rational use of antimicrobial drugs in outpatient practice. Eurasianclinical guidelines. 2016 // Pediatrics (Suppl. Consilium Medicum). 2017; 1: 17-25. (In Russ.)]

12. Стратегия предупреждения распространения антимикробной резистентности в Российской Федерации на период до 2030 года. Распоряжение Правительства Российской Федерации от 25 сентября 2017 г. № 2045-р. [Strategiya preduprezhdeniya rasprostraneniya antimikrobnoy rezistentnosti v Rossiyskoy Federatsii na period do 2030 goda. Rasporyazhenie Pravitelstva Rossiyskoy Federatsii ot 25 sentyabrya 2017 g. № 2045-r. (In Russ.)]

13. Методические рекомендации по рациональной антибиотикотерапии при инфекционных заболеваниях / Под ред. О. М. Драпкиной, С. Н. Авдеева, С. В. Яковлева. – М.: Видокс, 2019. – 56 с. [Guidelines for rational antibiotic therapy for infectious diseases. Ed. Drapkina O. M., Avdeev S. N., Yakovlev S. V. Moscow, 2019. 56 p.]

14. Kraus E. M., Pelzl S., Szecsenyi J., Laux G. Antibiotic prescribing for acute lower respiratory tract infections (LRTI) – guideline adherence in the German primary care setting: An analysis of routine data // PLoS One. 2017; 12 (3): e0174584. DOI: 10.1371/journal.pone.0174584.

15. Суханов Д. С. Современные особенности терапии острых бронхитов. Эффект и преимущества диспергируемой формы антибактериальных препаратов / Д. С. Суханов, В. С. Марьюшкина, Д. Ю. Азовцев // Лечащий Врач. – 2022. – 3 (25). – 70-75. DOI: 10.51793/OS.2022.25.3.011. [Sukhanov D. S., Maryushkina V. S., Azovtsev D. Yu. Modern features of acute bronchitis therapy. The effect and advantages of the dispersible form of antibacterial drugs // The Lechaschi Vrach Journal. 2022; 3 (25): 70-75.] URL: https://www.lvrach.ru/2022/03/15438251.

16. Таточенко В. К. Антибиотики в лекарственной форме солютаб / В. К. Таточенко // Современная педиатрия. – 2012. – 2 (42). – 69-72. [Tatochenko V. K. Antibiotics in solutab dosage form // Modern pediatrics. 2012; 2 (42): 69-72. (In Russ.)]

17. Wang C. Y., Lu C. Y., Hsieh Y. C. et al. Intramuscular ceftriaxone in comparison with oral amoxicillin-clavulanate for the treatment of acute otitis media in infants and children // J Microbiol Immunol Infect. 2004; 37 (1): 57-62.

18. Rimoin A. W., Hoff N. A., Fischer Walker C. L. et al. Treatment of streptococcal pharyngitis with once-daily amoxicillin versus intramuscular benzathine penicillin G in low-resource settings: a randomized controlled trial // Clin Pediatr. (Phila). 2011; 50 (6): 535-542.

19. Карпов О. И. Путь повышения эффективности и переносимости антибиотикотерапии при синусите у детей / О. И. Карпов // Детские инфекции. – 2006. – 3. – 52-56. [Karpov O. I. A way to improve the efficacy and tolerability of antibiotic therapy for sinusitis in children // Children's infections 2006; 3: 52-56. (In Russ.)]

20. Белоусов Ю. Б. Рациональная терапия острого тонзиллита: все ли препараты амоксициллина одинаковы? / Ю. Б. Белоусов, А. Н. Данилов, С. К. Зырянов // Consilium Medicum. – 2010. – 4. – 5-11. [Belousov Yu. B., Danilov A. N., Zyryanov S. K. Rational therapy of acute tonsillitis: are all amoxicillin preparations the same? // Consilium Medicum. 2010; 4: 5-11. (In Russ.)]

21. Переверзев А. П. Лечение инфекций верхних дыхательных путей: роль доксициклина / А. П. Переверзев [и др.] // Медицинский алфавит. – 2021. – (23): 29–36. DOI: 10.33667/2078-5631-2021-23-29-36 [Pereverzev A. P., Pereverzeva A. S., Kovaleva G. P., Ostroumova O. D. Treatment of upper respiratory tract infections: the role of doxycycline // Medical alphabet. 2021; (23): 29-36. (In Russ.)] DOI: 10.33667/2078-5631-2021-23-29-36.

22. Козлов Р. С. Эффективность диспергируемых таблеток амоксициллина в лечении острых бактериальных инфекций нижних дыхательных путей / Р. С. Козлов, А. А. Зайцев // Лечащий Врач. – 2017. – 10. – 12015. [Kozlov R. S., Zaytsev A. A. Efficacy of amoxicillin dispersible tablets in the treatment of acute bacterial infections of the lower respiratory tract // Lechaschi Vrach Journal. 2017; 10: 12015. (In Russ.)]

23. Qazi S. Management for Pneumonia in Developing Countries, WHO, Geneva, June 2013.

24. Овчинников А. Ю. Оптимизация антибактериальной терапии при лечении больных острым бактериальным риносинуситом / А. Ю. Овчинников, М. А. Эдже, А. Ю. Щербаков // Терапия. – 2016. – 6 (10). – 64–67. [Ovchinnikov A. Yu., Edzhe M. A., Shcherbakov A. Yu. Optimization of antibacterial therapy in the treatment of acute bacterial rhinosinusitis // Therapy. 2016; 6 (10): 64-67. (In Russ.)]

25. Yin H. S., Parker R. M., Sanders L. M. et al. Liquid medication errors and dosing tools: a randomized controlled experiment // Pediatrics. October 2016; 138 (4).

26. Yin H. S., Dreyer B. P., Moreira H. A., van Schaick L., Rodriguez L. et al. Liquid medication dosing errors in children; role of provider counseling strategies // Acad Pediatr. 2014; 14 (3): 262-270.